Wednesday, January 19

AstraZeneca’s Evusheld Antibody Treatment Neutralizes the Omicron Variant, According to Studies from the Universities of Oxford and Washington

AstraZeneca’s Evusheld drug, a long-acting antibody combination for the prevention of Covid-19, retains neutralizing activity against the omicron variant, according to new data from studies conducted by the University of Oxford, UK. United, and Washington, in the United States.

The data has been obtained from laboratory tests using real live viruses isolated from people who contracted the omicron variant. With these results, the effectiveness of Evusheld against the new variant of Covid-19, which is becoming prevalent among new infections, is demonstrated. So far, this drug from AstraZeneca, along with another from GSK, are the only two approved drugs that have been shown to be effective in studies against omicron.

Evusheld, in addition, has also been shown to retain activity against all variants of Covid-19 existing until now. This drug was designed to evade potential resistance to the emergence of new variants of the coronavirus, thanks to the combination of two particularly potent antibodies with different and complementary activities against the virus.

It has already received authorization for emergency use in the United States for prevention against the virus in people with immune compromise who cannot generate an adequate immune response to the Covid-19 vaccine.

The data reflected in three independent studies give Evusheld the confidence to avoid the disease in people with immunity problems. It is considered that around 2% of the world population has a greater risk of an inadequate response to the vaccines approved to prevent Covid-19, for whom it is extremely important that there are drugs such as Evusheld to prevent them from contracting the disease, which represents a greater danger for these types of people.

Leave a Reply

Your email address will not be published. Required fields are marked *